Skip to content
TFS TFS HealthScience | Contract Research Organization | Global Resourcing Provider | CRO

Oncology

Oncology expertise built on partnership, scientific depth and accountability

Supporting cancer therapies across 35+ indications with the experience, commitment and collaborative approach needed to move programmes forward with confidence.

Our teams work closely with sponsors throughout the development journey, staying connected to the science, objectives and challenges of each programme. By maintaining continuity of knowledge and open communication, we help teams make informed decisions and maintain momentum throughout development.

300+


Completed trials

8,000+


Investigator sites across 17 countries

15,000+


Patients enrolled

Scientific expertise across today’s oncology modalities

Oncology drug development is becoming increasingly precise and complex. Our teams bring deep therapeutic expertise, strong investigator relationships and practical operational experience across a broad range of treatment approaches.

From immune checkpoint inhibitors and antibody-drug conjugates to cell and gene therapies, we help sponsors navigate the scientific, clinical and operational challenges unique to each programme.

Haematologic malignancies

Leukemias · Lymphomas · Multiple myeloma

Solid Tumors

Breast cancer · Prostate cancer · Gastrointestinal cancers · Cervical cancer · Lung cancer

Rare and other cancers

Advanced and metastatic solid tumors · Neuroendocrine tumors · Sarcoma · Skin cancers · Supportive care

Joakim Jagorstrand

Vice President, Head of Oncology

“We are living through one of the most exciting periods in the history of cancer research. Advances in targeted therapies, immunotherapies, and cell-based treatments are transforming outcomes for patients across many cancers. Being part of that journey is both a privilege and a responsibility. It requires deep expertise, strong partnerships and an unwavering commitment to helping sponsors bring innovative therapies to the patients who need them most.”

Our oncology teams tailor their approach to the unique needs of each study, rather than applying one standard model to every trial.

How we secure your clinical pathway

Clinical continuum

Built-in flexibility, from a single CRA to full global trials.

Strategic resourcing, FSP and full-service clinical development, working as one team. Scale capacity across 40 countries, eliminating vendor handoffs while preserving protocol knowledge in the room the whole way through.

Therapeutic depth

Fast decisions through specialized clinical depth.

We restrict our focus to five complex therapeutic areas. Our specialized leads theyhold direct decision-making authority, fast-tracking approvals and solving site bottlenecks with scientific authority.

Teams that stay

True peers, driven by scientific urgency.

TFS holds an 88% retention rate, 8 points above the industry average. That means the senior scientific peer who joins your study is still there at database lock.

Trial security

Risk flagged early. Execution made visible.

Rooted in our Swedish heritage, we bring disciplined methodology and transparent communication to every study. We deliver real-time data integrity, flag protocol issues before they cost you time, and maintain regulatory compliance at every milestone.

One team, whether you need a single specialist or a full trial.

Clinical development

Access specialized clinical experts who integrate directly into your internal teams, matching your operational demands as they shift.
— Rapid deployment of validated
clinical professionals.

— Flexible capacity management 
tailored to pipeline shifts.

Strategic solutions

We embed life sciences expertise wherever your programme needs it: a single expert consultant, a dedicated FSP team, a hybrid model or a fully managed function. Every option draws on 60,000+ active professional profiles and runs on one continuum, with built-in flexibility, trial security and senior teams that stay from day zero.
— Expert consultants matched to your study, on average within five days.

— Dedicated FSP teams, line-managed by TFS and working to your SOPs.

— Hybrid models that combine FSP and full service under one governance.

— Managed functions we run for you, from oversight to systems.

End-to-end delivery

Full-service trial execution, backed by therapeutic depth and teams that stay.
— Full-lifecycle protocol management 
from design to database lock.

— Scientific leadership across 5 specialized 
therapeutic areas.

— Stable project teams ensuring continuous 
data quality and safety.

Quality Management

Three services. One independent quality function, standalone or embedded across your clinical portfolio.
— Audit & programme management: risk-based GxP audits to detect risks early and drive continuous improvement.

— Inspection readiness: targeted assessments, mock inspections and SME preparation for regulatory scrutiny.

— Quality oversight: ICH E6(R3)- and ICH E8(R1)-aligned oversight across studies and vendors.

Clinical operations & outsourcing FAQs.

What clinical outsourcing models does TFS provide?

We deliver three modular frameworks under a single contract: Strategic Resourcing, Functional Service Provider (FSP), and Full-Service Trials. This model elasticity allows you to scale clinical capacity fluidly as your pipeline demands, eliminating vendor handoffs.

What is the geographic footprint and reach of TFS?

Founded in Lund, Sweden, we operate as a global CRO with active regulatory and clinical reach across 40 countries. We combine comprehensive multi-region execution with specialized infrastructure and investigator networks across Europe and the Nordics.

How does TFS maintain clinical study continuity?

We maintain an industry-leading CRA turnover rate of 14%, significantly outperforming the 20% sector average. This team stability ensures consistent protocol knowledge, reduces management burden, and protects your data integrity.

Which therapeutic areas does TFS specialize in?

We concentrate our medical, clinical, and regulatory capabilities exclusively within five core areas: Dermatology, Internal Medicine, Neuroscience, Oncology, and Ophthalmology, backed by a track record of 1,800+ completed trials.